Avenue Therapeutics Inc. Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Avenue Therapeutics Inc. Stock
Our community identified positive and negative aspects for Avenue Therapeutics Inc. stock for the coming years. 3 users see the criterium "Company culture" as a plus for the Avenue Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Avenue Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Avenue Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Avenue Therapeutics Inc. | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | -0.980% | 1.000% | 12.849% | 13.483% | 9.189% | -53.670% | -58.264% |
| Rockwell Medical Inc. | -1.480% | 3.154% | -3.416% | -58.916% | -58.631% | -9.838% | -92.418% |
| Twist Bioscience Corp | -1.510% | 7.737% | 5.966% | -44.491% | -39.405% | 11.129% | -76.316% |
Comments
Avenue Therapeutics, Inc. (NASDAQ: ATXI) is now covered by analysts at Maxim Group. They set a "buy" rating and a $0.75 price target on the stock.
Show more
Ratings data for ATXI provided by MarketBeat
Avenue Therapeutics, Inc. (NASDAQ: ATXI) is now covered by analysts at Aegis. They set a "buy" rating and a $32.00 price target on the stock.
Show more
Ratings data for ATXI provided by MarketBeat
